Overview
Eitr Biologics develops next-generation immunotherapies to treat infectious diseases that threaten public health, with a focus on making lifesaving treatments globally accessible. Its work centers on immunotherapies that boost or modulate the immune response against infections, supported by a global network of academic and government labs. The company differentiates itself by prioritizing global accessibility and public-health impact, using its international collaborations to address unmet needs. Its goal is to provide lifesaving immunotherapies and expand worldwide access to these treatments to strengthen public health against current and emerging threats.
Work here?Claim your company
Simplify's take
What believers are saying
- NIH awarded $1 million on August 27, 2026 for betacoronavirus work.
- DoD awarded $100,000 in May 2026 for broad-spectrum nanobody development.
- Patent publication in July 2025 strengthens partnering leverage with vaccine and biodefense buyers.
What critics are saying
- No product approvals exist; revenue depends on NIH and DoD grants through 2027.
- Federal awards total only $39.6 million, leaving commercialization and financing fragile.
- If preclinical data disappoint, platform adoption dies before clinical validation.
What makes Eitr Biologics unique
- ODIN bispecific nanobodies are patent-protected and assigned in 2025.
- Eitr targets infectious diseases, spanning influenza and betacoronavirus programs.
- The company keeps operating from San Diego with a specialized, research-heavy footprint.
Help us improve and share your feedback! Did you find this helpful?